In the original article, there was a mistake in the legend for Figure 3 as published.
“TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. Two nanometer TSP1 is added for 10 min followed by 40 min of 50 ng/ml VEGF…” The correct legend appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
“TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. 2 nM TSP1 is added for 10 min followed by 40 min of 50 ng/ml VEGF…”
Incorrect Author Name
An author name was incorrectly spelled as Jeffery S. Isenberg. The correct spelling is Jeffrey S. Isenberg. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Text Correction
In the original article, there was an error on the Introduction section page 2, paragraph 3:
“…we set out here to interrogate potential mechanisms for the inhibition of VEGF/VEGFR2 signaling to ERK1/2 and calcium by TSP1/CD4 interaction utilizing a detailed rule-based model of VEGF signaling to ERK1/2 and calcium…”
A correction has been made to Introduction, paragraph 3:
“…we set out here to interrogate potential mechanisms for the inhibition of VEGF/VEGFR2 signaling to ERK1/2 and calcium by TSP1/CD47 interaction utilizing a detailed rule-based model of VEGF signaling to ERK1/2 and calcium…”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
In the original article, there was an error on the Conflict of Interest Statement:
“JI serves as chair of the scientific advisory boards of Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO).”
A correction has been made to Conflict of Interest Statement:
“JI serves as chair of the scientific advisory board of Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Statements
Conflict of interest
JI serves as chair of the scientific advisory board of Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO). The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Summary
Keywords
TSP1, CD47, VEGF, VEGFR2, computational modeling, calcium, ERK1/2
Citation
Bazzazi H, Isenberg JS and Popel AS (2017) Corrigendum: Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation. Front. Physiol. 8:147. doi: 10.3389/fphys.2017.00147
Received
09 February 2017
Accepted
24 February 2017
Published
07 March 2017
Volume
8 - 2017
Edited and reviewed by
Shayn Peirce-Cottler, University of Virginia, USA
Updates
Copyright
© 2017 Bazzazi, Isenberg and Popel.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hojjat Bazzazi hbazzazi@jhmi.edu
This article was submitted to Computational Physiology and Medicine, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.